Ischemic Stroke Clinical Trial
— DELPHI EFSOfficial title:
Delphi Early Feasibility Study (DELPHI EFS)
An early feasibility study to evaluate the safety and first pass effect technical assessment of Delphi Revascularization Device for clot retrieval in Anterior circulation ischemic stroke in the intracranial ICA, MCA M1 and proximal dominant MCA M2, up to 8hrs of symptom onset or Last Known Well (LKW).
Status | Recruiting |
Enrollment | 15 |
Est. completion date | January 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - at least 18 years of age at time of consent - The patient or patient's LAR has signed and dated an ICD using the Institutional Review Board (IRB) and Medtronic Approved ICD and agrees to comply with protocol requirements. Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization has been provided and signed by the patient or patient's LAR; - Has baseline National Institutes of Health Stroke Scale (NIHSS) = 8; - Able to be treated within 8 hours of stroke symptom onset or - Last Known Normal (LKN); - Confirmed LVO in the anterior circulation (i.e., intracranial ICA, M1 or proximal dominant M2) as confirmed by CTA or MRA; - Has a Pre-stroke Modified Rankin Score (mRS) = 1; - Has an Alberta Stroke Program Early CT Score (ASPECTS) 6 - 10; - Use of Solitaire device as primary approach to thrombectomy, with or without conjunct aspiration; If tPA is indicated, initiation of IV tPA should be administered as soon as possible to not delay usual care* and no later than 3.0 hours from onset of stroke symptoms or LKW, with investigator verification that the patient has received/is receiving the correct IV tPA dose (0.9mg/kg) for the estimated weight; and - Is ineligible for IV-tPA or failed to achieve recanalization (mTICI 2b or higher) of target large vessel occlusion after administration of IV-tPA. Exclusion Criteria: - Cannot provide consent or legally authorized representative not available to provide consent; - Has evidence of intracranial hemorrhage on CT or MRI; - Has known history of epilepsy; - Has recurrent stroke within last three months; - Has known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0; - Has baseline platelet count < 30.000 / µL; - Has baseline blood glucose of < 50mg/dL; - Has severe, sustained hypertension (SBP > 185mm Hg or DBP > 110 mm Hg); - Is Covid-19 positive or have active Covid-19 infection; - Female patient, of child-bearing potential, who is pregnant(confirmed with a positive pregnancy test) or breastfeeding at the time of admission or plans to become pregnant during their participation in the study; - Patient is participating in another clinical trial at any time during the duration of the study that could confound the treatment or outcomes of this investigation; and/or - Has a severe health condition that may potentially result in death within 6 months. - Patients with known nickel sensitivity. |
Country | Name | City | State |
---|---|---|---|
United States | kaledia Health/Buffalo General Medical Center/GVI | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
University at Buffalo |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate technical efficacy outcomes with radiographical measurements | • Overall post-procedure first pass revascularization success as defined by mTICI=2B using DSA; | Day 1 | |
Primary | outcomes with radiographical measurements | • Final mTICI post procedure using DSA | day 1 | |
Primary | Evaluate technical efficacy outcomes with radiographical measurements | • Target vessel re-occlusion within 3 days per CTA or MRA | 3 days | |
Primary | Evaluate technical efficacy outcomes with radiographical measurements | Comparison of predictive (via CTP) and final infarct (via MRI FLAIR) volumes at Day 3; and Final infarct volume via MRI FLAIR at 90 days. |
90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01983644 -
RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study
|
N/A |